Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase 3 2

Status

Completed 7Recruiting 4Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1

Conditions

Recurrence 1Prostatic Neoplasms 1Neoplasms 1Adenocarcinoma 1

Interventions

Carboplatin 106Cisplatin 97Paclitaxel 78pembrolizumab 69Gemcitabine 59Pemetrexed 49Cyclophosphamide 46Docetaxel 45Dexamethasone 45durvalumab 44Capecitabine 44Radiotherapy 40Nivolumab 37Lenalidomide 37Specimen Handling 36Doxorubicin 36Rituximab 34Oxaliplatin 34Bevacizumab 33Magnetic Resonance Spectroscopy 32Fluorouracil 32atezolizumab 29Etoposide 29Vincristine 26Radiation 26Leucovorin 26Letrozole 24Bortezomib 24Fulvestrant 23Prednisone 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × cabazitaxel × Clear all
NCT06691984 2026-05-15

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Amgen

Phase 3 Active not recruiting
707 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT01952223 2025-07-30

PEACE2

UNICANCER

Phase 3 Active not recruiting
761 enrolled

Adenocarcinoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡